LAVA’s bispecific gamma-delta T cell engagers (bsTCEs)
directly induce potent killing of tumor cells
via their unique targeting of Vγ9Vδ2 T cells and tumor associated antigens (TAAs).
via their unique targeting of Vγ9Vδ2 T cells and tumor associated antigens (TAAs).
They combine a variety of traits to accomplish this including:
Proof of principle of LAVA’s approach has been established by in vitro, in vivo and ex vivo studies in which gamma-delta bsTCEs demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA is advancing several novel gamma-delta bsTCEs towards clinical development.